Continuous versus Six Months a Year Maximal Androgen Blockade in the Management of Prostate Cancer: A Randomised Study

European Urology

Volumn 54, Issue 2, 2008, Pages 382-391

  Irani, Jacques ^a   Celhay, Olivier ^a   Hubert, Jacques ^b   Bladou, Franck ^c   Ragni, Evelyne ^d   Trape, Gérard ^e   Doré, Bertrand ^a  

^a POITIERS UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY HOSPITAL OF NANCY   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^d HÔPITAL NORD   (France)

^e Schering Plough   (France)

Author keywords

Prostate; Prostatic neoplasms; Quality of life; Questionnaires; Testosterone

Indexed keywords

ANDROGEN; FLUTAMIDE; GONADORELIN;

AGED; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

AGED; ANDROGEN ANTAGONISTS; FLUTAMIDE; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 45849110316     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2008.02.024     Document Type: Article

References (22)

1. Heidenreich A, Aus G, Abbou CC, et al. Guidelines of the European Association of Urology-Update March 2007-Guidelines on Prostate Cancer. Available at URL: http://www.uroweb.org/fileadmin/user_upload/Guidelines/07_Prostate_Cancer_2007.pdf.
2. Sännfalt K., Carlsson P., and Varenhorst E. Diffusion and economic consequences of health technologies in prostate cancer care in Sweden, 1991-2002. Eur Urol 49 (2006) 1028-1034
3. Wirth M.P., Hakenberg O.W., and Froehner M. Antiandrogens in the treatment of prostate cancer. Eur Urol 51 (2007) 306-314
4. Tunn U. The current status of intermittent androgen deprivation (IAD) therapy for prostate cancer: putting IAD under the spotlight. BJU Int 99 (2007) 19-22
5. Shaw G.L., Wilson P., Cuzick J., et al. International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: a meta-analysis of 1446 patients. BJU Int 99 (2007) 1056-1065
6. Lofters A., Juffs H.G., Pond G.R., and Tannock I.F. "PSA-it is": knowledge of serum prostate specific antigen and other causes of anxiety in men with metaststic prostate cancer. J Urol 168 (2002) 2516-2520
7. Aaronson N.K., Ahmedzai S., Bergman B., et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 85 (1993) 365-376
8. Spry N.A., Kristjanson L., Hooton B., et al. Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer. Eur J Cancer 42 (2006) 1083-1092
9. Herr H.W., and O'Sullivan M. Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. J Urol 163 (2000) 1743-1746
10. Albertsen P.C., Aaronson N.K., Muller M.J., Keller S.D., and Ware J.E.J. Health-related quality of life among patients with metastatic prostate cancer. Urology 49 (1997) 207-216
11. da Silva F.C., Fossa S.D., Aaronson N.K., et al. The quality of life of patients with newly diagnosed M1 prostate cancer: experience with EORTC clinical trial 30853. Eur J Cancer 32A (1996) 72-77
12. Pettersson B., Varenhorst E., Petas A., and Sandow J. Duration of testosterone suppression after a 9.45 mg implant of the GnRH-analogue buserelin in patients with localised carcinoma of the prostate: a 12-month follow-up study. Eur Urol 50 (2006) 483-489
13. Oefelein M.G. Health related quality of life using serum testosterone as the trigger to re-dose long acting depot luteinizing hormone-releasing hormone agonists in patients with prostate cancer. J Urol 169 (2003) 251-255
14. Oefelein M.G. Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration. J Urol 160 (1998) 1685-1688
15. Gulley J.L., Figg W.D., Steinberg S.M., Carter J., Hussain M.H., and Dahut W.L. A prospective analysis of the time to normalisation of serum androgens following 6 months of androgen deprivation therapy in patients on a randomised phase III clinical trial using limited hormonal therapy. J Urol 173 (2005) 1567-1571
16. Nejat R.J., Rashid H.H., Bagiella E., Katz A.E., and Nenson M.C. A prospective analysis of time to normalisation of serum testosterone after withdrawal of androgen deprivation therapy. J Urol 164 (2000) 1891-1894
17. Pickles T., Agranovich A., Berthelet E., et al. Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinoma. Cancer 94 (2002) 362-367
18. Albrecht W., Collette L., Fava C., et al. Intermittent maximal androgen blockade in patients with metastatic prostate cancer: an EORTC feasibility study. Eur Urol 44 (2003) 505-511
19. Sato N., Akakura K., Isaka S., et al. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study. Urology 64 (2004) 341-345
20. Tunn U.V., Eckart O., Offenbach D.E., et al. Can intermittent androgen deprivation be an alternative to continuous androgen withdrawal in patients with PSA-relapse? First results of the randomized prospective phase-III clinical trial EC 507. J Urol 169 Suppl 4 (2003) 1481a
21. Schasfoort E., Heathcote P., Lock T., et al. Intermittent androgen suppression for the treatment of advanced prostate cancer. J Urol 169 (2003) 1483a
22. Studer U.E., Collette L., Whelan P., et al. Baseline PSA and PSA doubling time predict the risk of objective progression and death in patients with T0-4 N0-2 M0 prostate cancer on watchful waiting. J Urol 175 Suppl (2006) 215 (abstract no. 665)